Please use this identifier to cite or link to this item: http://ahro.austin.org.au/austinjspui/handle/1/22218
Title: Treatment selection for first-line metastatic renal cell carcinoma in Australia: Impact of new therapy options.
Authors: Schmidt, Andrew;Azad, Arun;Goh, Jeffrey;Harris, Carole;Joshua, Anthony M;Weickhardt, Andrew;Krieger, Laurence
Affiliation: Liz Plummer Cancer Centre, Cairns, Queensland, Australia
Peter McCallum Cancer Centre, Melbourne, Victoria, Australia
Royal Brisbane and Women's Hospital, Butterfield Street, Herston & University of Queensland, St Lucia, Queensland, Australia
St George Hospital and Sutherland Clinical School UNSW, Kogarah, New South Wales, Australia
The Kinghorn Cancer Centre, Darlinghurst, New South Wales, Australia
Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia
Royal North Shore Hospital, Reserve Rd, St Leonards, Northern Cancer Institute, St. Leonards, New South Wales, Australia
Issue Date: Nov-2019
Citation: Asia-Pacific journal of clinical oncology 2019; 15 Suppl 10: 3-10
Abstract: Vascular endothelial growth factor receptor tyrosine kinase inhibitors have provided an effective standard of care for the treatment of metastatic clear cell renal cell carcinoma (mRCC). Survival is prolonged with emergence of modern immuno-oncology combination regimens. Prognostic risk assessment is essential for choosing between these therapies to determine the most appropriate first line treatment option, with selection based on International Metastatic RCC Database Consortium Risk Category. We review the current subsidized first line treatments for mRCC in Australia and consider the evidence for treatment selection and sequencing.
URI: http://ahro.austin.org.au/austinjspui/handle/1/22218
DOI: 10.1111/ajco.13289
PubMed URL: 31762165
Type: Journal Article
Subjects: VEGF tyrosine kinase inhibitors
immuno-oncology
renal cell carcinoma
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.